Nebilet (Nebivolol Hydrochloride)

Nebivolol Hydrochloride, the active ingredient in Nebilet, is a beta blocker presented as a tablet for oral use. It is indicated for the management of hypertension and heart failure in adult patients, offering blood pressure reduction and improved cardiac function.

GNH USA supplies Nebilet as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution. Customers benefit from comprehensive regulatory support and consistent product availability across multiple markets.

Nebilet is a selective β1‑adrenergic antagonist used in cardiovascular disease management.

Hypertension: lowers systolic and diastolic blood pressure to reduce cardiovascular risk. Heart failure: improves left‑ventricular function and decreases hospitalization rates. Elderly patients with hypertension: provides effective blood pressure control with a favorable tolerability profile.

Nebilet may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Headache: mild to moderate intensity. - Dizziness or light‑headedness, especially on standing. - Fatigue or tiredness during the initial treatment period. - Bradycardia: slower than normal heart rate. - Nausea or mild gastrointestinal upset. - Peripheral edema: swelling of the lower limbs.

Serious or Rare Side Effects: - Severe bradycardia or heart block requiring medical attention. - Marked hypotension leading to fainting or shock. - Bronchospasm in patients with reactive airway disease. - Acute heart failure decompensation. - Allergic reactions such as rash, angioedema, or anaphylaxis.

Before initiating Nebilet, clinicians should assess patient-specific factors and monitor for potential risks.

Monitor blood pressure: ensure adequate control without excessive hypotension. Assess cardiac function: evaluate heart rate and ECG for bradyarrhythmias. Use caution in asthma or chronic obstructive pulmonary disease: β‑blockade may exacerbate bronchospasm. Avoid abrupt discontinuation: taper dose to prevent rebound hypertension. Adjust dose in renal impairment: consider reduced dosing in severe kidney dysfunction. Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Nebilet can interact with several drug classes; awareness helps prevent adverse outcomes.

Major Interactions (Avoid): - Other β‑blockers: additive negative chronotropic effects. - Calcium‑channel blockers (verapamil, diltiazem): may cause profound bradycardia or AV block. - Antiarrhythmic agents (amiodarone, quinidine): increase risk of cardiac conduction disturbances. - Insulin or oral hypoglycemics: may mask hypoglycemia symptoms. - Clonidine withdrawal: can precipitate severe hypertension.

Moderate Interactions (Monitor Closely): - NSAIDs: may blunt antihypertensive effect. - Diuretics: monitor electrolytes and renal function. - ACE inhibitors or ARBs: watch for additive blood‑pressure lowering. - CYP2D6 inhibitors (fluoxetine, paroxetine): may raise nebivolol plasma levels. - Antidepressants (tricyclics): increase risk of cardiac side effects.